Brain cell activity behind insomnia after long-term heavy drinking
Hypothalamic Neuronal Activity During Insomnia Induced by Chronic Ethanol Exposure
Researchers are looking at whether overactive wake‑promoting brain cells and underactive sleep‑promoting brain cells cause the severe insomnia people get when they stop heavy drinking.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11132718 on NIH RePORTER |
What this research studies
This work uses a mouse model of chronic intermittent alcohol exposure to mirror the insomnia people often get during withdrawal. Scientists will use tiny deep‑brain microscopes to record calcium signals from hypothalamic orexin (wake‑promoting) and GABA (sleep‑promoting) neurons during wake, NREM, and REM sleep before, during, and after alcohol exposure. They will then use pharmacogenetic tools to increase or decrease activity in those neurons to see if changing their balance can restore normal sleep patterns. The goals are to pinpoint the neural imbalance that drives withdrawal insomnia and identify targets for future treatments.
Who could benefit from this research
Good fit: Adults with alcohol dependence who experience severe insomnia when they try to stop drinking are the population most likely to benefit from research based on these findings.
Not a fit: People whose sleep problems are caused by other conditions (for example primary insomnia, sleep apnea, or unrelated psychiatric disorders) may not benefit directly from results focused specifically on alcohol‑withdrawal sleep changes.
Why it matters
Potential benefit: If successful, this could point to new treatments to reduce withdrawal insomnia and help prevent relapse to drinking.
How similar studies have performed: Prior animal work supports orexin overactivity and reduced GABA signaling during alcohol withdrawal, but combining in‑vivo calcium imaging with pharmacogenetic control in this context is relatively new.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Blanco-Centurion, Carlos a. — Medical University of South Carolina
- Study coordinator: Blanco-Centurion, Carlos a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.